Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
RA

NASDAQ · RARE

Ultragenyx Pharmaceutical Inc.

Healthcare · Biotechnology

$14.46

Down-$0.04 (-0.28%)

Updated Oct 7, 2026, 2:15 AM

SID Score

3.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.49B
P/E ratio
-6.23
Dividend yield
0.00%
52-week range
$12.73 – $39.89
Volume
3.89M
Avg. volume
1.5M

Price performance · RARE

RARE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RARE closed at $14.46 after 21 trading sessions, down 2.82% for the selected period.

Last close
$14.46
Period change
-2.82%
Period low
$12.88
Period high
$15.62
Daily close
View OHLC price history
RARE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$14.60$14.70$14.08$14.463.89M
Oct 5, 2026$15.25$15.31$14.21$14.504.66M
Oct 2, 2026$14.90$15.28$14.67$15.223.88M
Oct 1, 2026$15.03$15.25$14.62$14.754.12M
Sep 30, 2026$15.475$15.53$14.86$15.034.42M
Sep 29, 2026$14.455$15.50$14.11$15.325.88M
Sep 28, 2026$14.33$14.47$14.11$14.414.94M
Sep 25, 2026$14.87$14.94$14.1508$14.504.31M
Sep 24, 2026$14.73$14.87$14.545$14.773.49M
Sep 23, 2026$15.40$15.4979$14.54$14.885.71M
Sep 22, 2026$14.78$16.12$14.475$15.6158.13M
Sep 21, 2026$14.58$15.01$14.275$14.655.27M
Sep 18, 2026$14.79$15.07$14.07$14.5113.34M
Sep 17, 2026$13.22$14.575$13.20$14.5012.43M
Sep 16, 2026$13.07$13.22$12.73$12.885.03M
Sep 15, 2026$13.56$13.59$12.88$13.075.66M
Sep 14, 2026$14.44$14.4444$13.60$13.615.93M
Sep 11, 2026$14.43$14.70$14.13$14.303.25M
Sep 10, 2026$14.25$14.44$13.95$14.403.67M
Sep 9, 2026$14.77$15.1947$14.27$14.314.58M
Sep 8, 2026$15.097$15.25$14.6283$14.885.93M

Latest RARE news

The latest Smart Investors Daily articles mentioning RARE.

Stock researchCompany · Overview

RARE research

Overview

Company profile and research snapshot.

Company profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$50.00
Implied upside
—
Analysts
—
RARE recent ratings
DateFirmRatingTarget
Sep 21, 2026Evercore ISI GroupIn-Line—
Sep 21, 2026BarclaysOverweight—
Sep 18, 2026Morgan StanleyEqual-Weight—
Sep 18, 2026CitigroupBuy—
Sep 18, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. EMA validation confirms that the application is sufficiently complete for the Agency to begin its formal scientific review. Validation

Yahoo · Sep 22, 2026

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just added another commercial product to its portfolio. The FDA on September 17 approved Fayuvi for the treatment of neurologic manifestations of Sanfilippo syndrome Type A in pediatric patients with preserved neurodevelopmental function. Fayuvi becomes the first approved treatment for this rare and fatal childhood disorder. Ultragenyx stock jumped more than […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By